bioAffinity Technologies, Inc. filed a Form 8-K on November 20, 2026, reporting stockholder votes on five proposals at a Special Meeting held the same day, including an approved amendment to its Certificate of Incorporation decreasing authorized common shares from 350,000,000 to 200,000,000.
Key Highlights
- Authorized shares reduced: Stockholders approved decreasing total authorized common stock from 350,000,000 shares to 200,000,000 shares, effective upon filing with the Delaware Secretary of State on November 20, 2026.
- August warrant proposal approved: Stockholders approved the issuance of up to 1,128,272 shares of common stock issuable upon exercise of warrants from a private placement that closed on August 14, 2026.
- October warrant proposal approved: Stockholders approved the issuance of up to 980,072 shares of common stock issuable upon exercise of warrants from a private placement that closed on October 8, 2026.
- Non-public offerings authorized: Stockholders approved the issuance of securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d).
- Record date shares outstanding: As of the September 23, 2026 record date, there were 1,166,625 shares of common stock outstanding and entitled to vote.
- Adjournment not needed: The adjournment proposal was approved but not exercised, as all four substantive proposals passed at the Special Meeting.
bioAffinity Technologies Special Meeting Results and Charter Amendment Details
According to the filing, bioAffinity Technologies, Inc. (NASDAQ:BIAF) held a Special Meeting of Stockholders on November 20, 2026, at which five proposals were presented for a vote. Stockholders were entitled to one vote per share of common stock held as of the September 23, 2026 record date, when 1,166,625 shares were outstanding and entitled to vote.
The most structurally significant action, the company disclosed, was the approval of Proposal No. 4, which amended the Certificate of Incorporation to reduce total authorized shares of common stock, par value $0.007 per share, from 350,000,000 to 200,000,000. That proposal received 319,130 votes for and 149,445 votes against, with 57,191 abstentions and no broker non-votes. The company reported that the Certificate of Amendment was filed with the Delaware Secretary of State on November 20, 2026, and "became effective immediately upon filing."
The filing also reported approval of two warrant exercise proposals tied to separate private placement offerings. Proposal No. 1, covering up to 1,128,272 shares from warrants issued in connection with the August 14, 2026 private placement, received 61,862 votes for and 35,286 against, with 427,784 broker non-votes. Proposal No. 2, covering up to 980,072 shares from warrants tied to the October 8, 2026 private placement, received 61,180 votes for and 33,081 against, again with 427,784 broker non-votes. Proposal No. 3, authorizing securities issuances in non-public offerings under Nasdaq Marketplace Rule 5635(d), received 50,700 votes for and 28,910 against. The adjournment proposal (Proposal No. 5) was approved with 308,230 votes for but was described by the company as unnecessary given the passage of the other four proposals.
What Was Disclosed
bioAffinity Technologies reported the results of five stockholder votes at a November 20, 2026 Special Meeting and disclosed that an amendment reducing authorized common shares from 350,000,000 to 200,000,000 became effective the same day upon filing with the State of Delaware.



Please wait processing your request...